Developer docs
API playgroundTry for free, no card

Search company profiles

Visiopharm

Full company profile

uuid0002fhz

Namestring
Visiopharm
Legal namestring
Visiopharm A/S
Websiteurl
visiopharm.com
Company typeenum
Private
Founded yearint
2002
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHørsholm, Denmark
HQ citystring
Hørsholm
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, tissue image analysis, AI pathology solutions, spatial biology analysis, diagnostic decision support
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Services-Health Services8000
Product category
Digital Pathology Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Software Licenses
TypeSubscription Recurring
Description

Sale of pathology image analysis software for research and diagnostic applications. Products include Discovery, Phenoplex, and diagnostic APPs.

visiopharm.com
2Software Maintenance Service
TypeSubscription Recurring
Description

Subscription-based software maintenance providing access to latest product versions, bug fixes, compatibility updates, and unlimited technical support. Protects software investment and ensures access to newest features.

visiopharm.com
3Professional Services
TypeProfessional Services
Description

Application support hours sold as 4 or 8 hour Professional Online Support packages including guidance for image analysis, technical advice, workflow optimization, and custom project consulting.

visiopharm.com
4Training Services
TypeProfessional Services
Description

Academy training programs and product training services for customers to learn how to use Visiopharm software effectively.

visiopharm.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels10 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Software Maintenance Subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Annual subscription providing unlimited technical support, software updates, and latest product versions. Complimentary support included for first-year warranty customers or those with Professional Online Support package.

visiopharm.com
2Professional Online Support (Application)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Application support hours available in 4 or 8 hour packages for custom project guidance, image analysis advice, and workflow optimization.

visiopharm.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Discovery
Description

AI-powered tissue image analysis software platform enabling researchers to train deep learning models for accurate and reproducible results.

visiopharm.com
+5 more records
Core offering1 text field

Visiopharm develops and sells AI-driven precision pathology software for tissue image analysis in both research and clinical diagnostics. Its platform combines deep learning algorithms with 20 years of pathology expertise, offering core products (Discovery, Phenoplex, Insight for Diagnostics), add-on modules (Qualitopix, Tissuealign, Tissuearray), and a library of over 130 modular analysis APPs. The portfolio includes nine IVDR-cleared CE-IVD diagnostic algorithms for clinical decision support in cancer diagnostics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Invasive tumor detection DICE score of 0.944 at Odense University Hospital, 0.81 at Pathology Diagnostics Jarutat, and 0.908 at University Medical Center Groningen (mean 0.888)
+2 more records
Product overview1 text field

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. The company offers a platform-plus-modules architecture combining core analysis engines (Discovery for research, Phenoplex for spatial biology, Insight for diagnostics) with specialized add-on modules (Qualitopix for IHC quality, Tissuealign for image alignment, Tissuearray for TMA de-arraying). The product portfolio includes over 130 modular analysis APPs in the APP Center, nine CE-IVD cleared diagnostic algorithms, and OEM scanner integrations (Hamamatsu NDP.Analyze, Grundium Ocus, Philips UltraFast). The platform is built on Visiopharm Engine (AI execution) and Author AI (custom APP development) technologies, enabling analysis across H&E, IHC, multiplex fluorescence, and RNA ISH modalities. Founded in 2002, the company serves over 750 customer accounts in more than 40 countries.

Product and service9 records
1Discovery
CategoryCore Platform
Description

AI-powered tissue image analysis software for research applications. Enables pathologists and research scientists to train custom deep learning APPs for accurate and reproducible results without requiring programming expertise.

2Phenoplex
CategoryCore Platform
Description

Complete image analysis workflow for multiplexed spatial biology images. Enables spatial neighborhood analysis and cell phenotyping from multiplex fluorescence imaging data.

3Insight for Diagnostics
CategoryCore Platform
Description

Diagnostic decision support platform featuring IVDR-certified CE-IVD applications for clinical pathology workflows, providing diagnostic algorithms for biomarker assessment in cancer diagnostics.

4Qualitopix
CategoryAdd-on Module
Description

IHC staining consistency measurement and documentation tool that uses standardized analysis of next-generation reference materials to measure and document staining consistency in immunohistochemistry workflows.

5Tissuealign
CategoryAdd-on Module
Description

Image alignment module that aligns serial tissue sections at the cellular level for co-registration and co-localization analysis across different stains or biomarkers, enabling virtual multiplex staining workflows.

6Tissuearray
CategoryAdd-on Module
Description

Tissue micro-array de-arraying tool that automates the processing and analysis of tissue cores in TMAs for high-throughput tissue research.

7APP Center
CategoryAdd-on Module
Description

Library of over 130 modular analysis units (APPs) covering all tissue, stain, and modality types. Apps address specific analysis problems including cancer biomarkers, tumor microenvironment, spatial biology, and research applications, and can be used as building blocks for custom workflows.

8CE-IVD Diagnostic APPs
CategoryDiagnostic Module
Description

Nine IVDR-cleared diagnostic algorithms providing diagnostic decision support for clinical pathology. Applications include ER, PR, Ki-67, HER2 Breast Cancer AI, Invasive Tumor Detection (PDS) APP, and other biomarker quantification tools for cancer diagnostics.

9Pharma Services
CategoryService
Description

Contract research services for pharmaceutical companies using Visiopharm's AI-powered image analysis platform, supporting drug discovery, biomarker analysis, and clinical trial research needs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Visiopharm is OEM for Hamamatsu's NDP.Analyze software. Hamamatsu is an authorized worldwide distributor of Visiopharm's image analysis and stereology software for research use only.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Global life sciences company and authorized distributor of Visiopharm products, collaborating on digital pathology ecosystem and demonstrating integrated workflows at events like USCAP 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Spatial biology company and authorized distributor, with Visiopharm developing specific APPs for Akoya's Opal Multiplex IHC Detection Kits for tumor microenvironment analysis.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Digital pathology platform company and authorized distributor offering Visiopharm's AI-powered image analysis solutions to their customer base.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Visiopharm's image analysis software in North America and Asia regions.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Visiopharm's image analysis software in Asia region.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Visiopharm's image analysis solutions in China.

8Inter Instrument AS
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Visiopharm's image analysis and stereology solutions in Norway.

visiopharm.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Visiopharm's image analysis and stereology software in Brazil.

10Jinan Danjier
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Visiopharm's image analysis software in Asia.

visiopharm.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Finnish digital pathology scanner company acquired Visiopharm in May 2026 to create an integrated precision pathology platform combining digital slide scanning with AI-powered diagnostic applications. The acquisition builds on a pre-existing partnership and integration between the two firms.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration on NerValence AI-assisted digital pathology tool for analyzing skin biopsy samples in Parkinson's disease drug trials. Visiopharm provided AI analysis capabilities for the Syn-One biomarker services platform.

Strategic tierCoreTypeTechnology or Integration
Description

Integration of Visiopharm's AI products into PathAI's AISight Image Management System, enhancing digital pathology workflows with algorithms for prostate, breast, and lung cancer diagnostics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital pathology platform offering AI-powered image analysis for research and diagnostics; both channel partner and competitor. Serves biopharma and diagnostic labs with a cloud-native platform and Concentriq IMS - directly comparable use case and customer base.

TypeDirect peer
Description

AI pathology company building diagnostic and translational AI for cancer; integrated with Visiopharm's AI into AISight IMS. Operates in the same IVD/IHC diagnostic decision-support space with overlapping pharma and lab customers.

TypeDirect peer
Description

Developer of Halo image analysis platform for digital pathology, including multiplex phenotyping, IHC quantification, and AI-assisted diagnostics. Closely comparable to Visiopharm's Discovery and Phenoplex offerings for research and clinical workflows.

TypeBroad incumbent
Description

Established digital pathology incumbent with whole-slide imaging scanners, image management, and AI algorithms, including recent Aperio GT IVD/Dx capabilities - competes for the same clinical pathology lab budget as Visiopharm's Insight platform.

TypeBroad incumbent
Description

Healthcare major's pathology business offers UltraFast scanners and Intellisite pathology solution with image management; supported as a Visiopharm integration target. Represents enterprise competition for hospital system deployments.

TypeBroad incumbent
Description

Whole-slide scanner maker and OEM/distributor of Visiopharm (NDP.Analyze brand), NanoZoomer scanners are supported within Visiopharm workflows. Comparable in that Hamamatsu bundles image-analysis and scanner stack into enterprise pathology bids.

TypeEmerging player
Description

Spatial biology company offering Phenoptics and CODEX multiplex imaging, partnered with Visiopharm for co-developed APPs. Overlaps in multiplex tumor microenvironment workflows and competes for spatial biology translational pharma budgets.

TypeEmerging player
Description

Clinical AI pathology company with CE-IVD-cleared algorithms for breast, prostate, and gastric cancer detection - direct rival to Visiopharm's IVDR algorithms in EU diagnostic labs seeking clinical decision support.

9QuPath
TypeEmerging player
Description

Open-source whole-slide image analysis platform widely adopted in academic pathology research. Represents low-cost alternative competing for research budgets that Visiopharm's Discovery platform targets.

TypeBroad incumbent
Description

Pharma-major-affiliated digital pathology ecosystem targeting companion diagnostics and IVD labs. Competes for the largest reference labs and integrated healthcare systems that Visiopharm also seeks to win in cancer diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Visiopharm

Digital Pathology Softwarevisiopharm.com

Visiopharm firmographics

Firmographics
Name
Visiopharm
Legal name
Visiopharm A/S
Website
https://visiopharm.com
Company type
Private
Founded year
2002
Operating status
Acquired
Headcount range
51–100 employees
Ownership category
akta.pro rank

Visiopharm industry classification

Industry
Product category
Digital Pathology Software
NAICS
Medical Equipment and Supplies Manufacturing (3391), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital pathology software
  • Tissue image analysis
  • AI pathology solutions
  • Spatial biology analysis
  • Diagnostic decision support

Where Visiopharm is headquartered

Location

Headquarters

HQ city
Hørsholm
HQ country
Denmark
HQ region
Europe

Offices5 records

Markets served

Visiopharm business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Licenses: Sale of pathology image analysis software for research and diagnostic applications. Products include Discovery, Phenoplex, and diagnostic APPs.
  2. Software Maintenance Service: Subscription-based software maintenance providing access to latest product versions, bug fixes, compatibility updates, and unlimited technical support. Protects software investment and ensures access to newest features.
  3. Professional Services: Application support hours sold as 4 or 8 hour Professional Online Support packages including guidance for image analysis, technical advice, workflow optimization, and custom project consulting.
  4. Training Services: Academy training programs and product training services for customers to learn how to use Visiopharm software effectively.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSoftware Maintenance Subscription
Unit PricingPay-as-you-goProfessional Online Support (Application)

Go-to-market motion2 records

Distribution channels10 records

Marketing channels7 records

Visiopharm product offering

Product offering

Core offering

Visiopharm develops and sells AI-driven precision pathology software for tissue image analysis in both research and clinical diagnostics. Its platform combines deep learning algorithms with 20 years of pathology expertise, offering core products (Discovery, Phenoplex, Insight for Diagnostics), add-on modules (Qualitopix, Tissuealign, Tissuearray), and a library of over 130 modular analysis APPs. The portfolio includes nine IVDR-cleared CE-IVD diagnostic algorithms for clinical decision support in cancer diagnostics.

Product overview

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. The company offers a platform-plus-modules architecture combining core analysis engines (Discovery for research, Phenoplex for spatial biology, Insight for diagnostics) with specialized add-on modules (Qualitopix for IHC quality, Tissuealign for image alignment, Tissuearray for TMA de-arraying). The product portfolio includes over 130 modular analysis APPs in the APP Center, nine CE-IVD cleared diagnostic algorithms, and OEM scanner integrations (Hamamatsu NDP.Analyze, Grundium Ocus, Philips UltraFast). The platform is built on Visiopharm Engine (AI execution) and Author AI (custom APP development) technologies, enabling analysis across H&E, IHC, multiplex fluorescence, and RNA ISH modalities. Founded in 2002, the company serves over 750 customer accounts in more than 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Discovery: AI-powered tissue image analysis software platform enabling researchers to train deep learning models for accurate and reproducible results.
  • Phenoplex
  • Insight
  • Qualitopix
  • Tissuealign
  • Tissuearray

Products and services

  • Discovery AI-powered tissue image analysis software for research applications. Enables pathologists and research scientists to train custom deep learning APPs for accurate and reproducible results without requiring programming expertise.
  • Phenoplex Complete image analysis workflow for multiplexed spatial biology images. Enables spatial neighborhood analysis and cell phenotyping from multiplex fluorescence imaging data.
  • Insight for Diagnostics Diagnostic decision support platform featuring IVDR-certified CE-IVD applications for clinical pathology workflows, providing diagnostic algorithms for biomarker assessment in cancer diagnostics.
  • Qualitopix IHC staining consistency measurement and documentation tool that uses standardized analysis of next-generation reference materials to measure and document staining consistency in immunohistochemistry workflows.
  • Tissuealign Image alignment module that aligns serial tissue sections at the cellular level for co-registration and co-localization analysis across different stains or biomarkers, enabling virtual multiplex staining workflows.
  • Tissuearray Tissue micro-array de-arraying tool that automates the processing and analysis of tissue cores in TMAs for high-throughput tissue research.
  • APP Center Library of over 130 modular analysis units (APPs) covering all tissue, stain, and modality types. Apps address specific analysis problems including cancer biomarkers, tumor microenvironment, spatial biology, and research applications, and can be used as building blocks for custom workflows.
  • CE-IVD Diagnostic APPs Nine IVDR-cleared diagnostic algorithms providing diagnostic decision support for clinical pathology. Applications include ER, PR, Ki-67, HER2 Breast Cancer AI, Invasive Tumor Detection (PDS) APP, and other biomarker quantification tools for cancer diagnostics.
  • Pharma Services Contract research services for pharmaceutical companies using Visiopharm's AI-powered image analysis platform, supporting drug discovery, biomarker analysis, and clinical trial research needs.

Quantifiable outcome

  • Invasive tumor detection DICE score of 0.944 at Odense University Hospital, 0.81 at Pathology Diagnostics Jarutat, and 0.908 at University Medical Center Groningen (mean 0.888)
  • +2 more outcomes

Companies that use Visiopharm

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Visiopharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability12 records

Feature10 records

Visiopharm partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, core, major and minor.

  • Hamamatsu PhotonicsflagshipChannel Partner/ Reseller/ DistributorVisiopharm is OEM for Hamamatsu's NDP.Analyze software. Hamamatsu is an authorized worldwide distributor of Visiopharm's image analysis and stereology software for research use only.
  • Agilent TechnologiesflagshipChannel Partner/ Reseller/ DistributorGlobal life sciences company and authorized distributor of Visiopharm products, collaborating on digital pathology ecosystem and demonstrating integrated workflows at events like USCAP 2026.
  • Akoya BiosciencescoreChannel Partner/ Reseller/ DistributorSpatial biology company and authorized distributor, with Visiopharm developing specific APPs for Akoya's Opal Multiplex IHC Detection Kits for tumor microenvironment analysis.
  • ProsciacoreChannel Partner/ Reseller/ DistributorDigital pathology platform company and authorized distributor offering Visiopharm's AI-powered image analysis solutions to their customer base.
  • Evident (Olympus)majorChannel Partner/ Reseller/ DistributorAuthorized distributor for Visiopharm's image analysis software in North America and Asia regions.
  • ZEISSmajorChannel Partner/ Reseller/ DistributorAuthorized distributor for Visiopharm's image analysis software in Asia region.
  • BYTE ConsultingminorChannel Partner/ Reseller/ DistributorAuthorized distributor for Visiopharm's image analysis solutions in China.
  • Inter Instrument ASminorChannel Partner/ Reseller/ DistributorAuthorized distributor for Visiopharm's image analysis and stereology solutions in Norway.
  • SellexminorChannel Partner/ Reseller/ DistributorAuthorized distributor for Visiopharm's image analysis and stereology software in Brazil.
  • Jinan DanjierminorChannel Partner/ Reseller/ DistributorAuthorized distributor for Visiopharm's image analysis software in Asia.
  • GrundiumcoreStrategic or Co-development PartnerFinnish digital pathology scanner company acquired Visiopharm in May 2026 to create an integrated precision pathology platform combining digital slide scanning with AI-powered diagnostic applications. The acquisition builds on a pre-existing partnership and integration between the two firms.
  • CND Life SciencesmajorStrategic or Co-development PartnerCollaboration on NerValence AI-assisted digital pathology tool for analyzing skin biopsy samples in Parkinson's disease drug trials. Visiopharm provided AI analysis capabilities for the Syn-One biomarker services platform.
  • PathAIcoreTechnology or IntegrationIntegration of Visiopharm's AI products into PathAI's AISight Image Management System, enhancing digital pathology workflows with algorithms for prostate, breast, and lung cancer diagnostics.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Visiopharm competitors and assessment

Company assessment

Direct peers

  • Proscia: Digital pathology platform offering AI-powered image analysis for research and diagnostics; both channel partner and competitor. Serves biopharma and diagnostic labs with a cloud-native platform and Concentriq IMS - directly comparable use case and customer base.
  • PathAI: AI pathology company building diagnostic and translational AI for cancer; integrated with Visiopharm's AI into AISight IMS. Operates in the same IVD/IHC diagnostic decision-support space with overlapping pharma and lab customers.
  • Indica Labs: Developer of Halo image analysis platform for digital pathology, including multiplex phenotyping, IHC quantification, and AI-assisted diagnostics. Closely comparable to Visiopharm's Discovery and Phenoplex offerings for research and clinical workflows.

Broad incumbents

  • Aperio (Leica Biosystems): Established digital pathology incumbent with whole-slide imaging scanners, image management, and AI algorithms, including recent Aperio GT IVD/Dx capabilities - competes for the same clinical pathology lab budget as Visiopharm's Insight platform.
  • Philips Digital Pathology: Healthcare major's pathology business offers UltraFast scanners and Intellisite pathology solution with image management; supported as a Visiopharm integration target. Represents enterprise competition for hospital system deployments.
  • Hamamatsu Photonics: Whole-slide scanner maker and OEM/distributor of Visiopharm (NDP.Analyze brand), NanoZoomer scanners are supported within Visiopharm workflows. Comparable in that Hamamatsu bundles image-analysis and scanner stack into enterprise pathology bids.
  • Roche (uPath/Aperio combo): Pharma-major-affiliated digital pathology ecosystem targeting companion diagnostics and IVD labs. Competes for the largest reference labs and integrated healthcare systems that Visiopharm also seeks to win in cancer diagnostics.

Emerging players

  • Akoya Biosciences: Spatial biology company offering Phenoptics and CODEX multiplex imaging, partnered with Visiopharm for co-developed APPs. Overlaps in multiplex tumor microenvironment workflows and competes for spatial biology translational pharma budgets.
  • Ibex Medical Analytics: Clinical AI pathology company with CE-IVD-cleared algorithms for breast, prostate, and gastric cancer detection - direct rival to Visiopharm's IVDR algorithms in EU diagnostic labs seeking clinical decision support.
  • QuPath: Open-source whole-slide image analysis platform widely adopted in academic pathology research. Represents low-cost alternative competing for research budgets that Visiopharm's Discovery platform targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Visiopharm social profiles

Digital presence

Visiopharm compliance and trust

Trust signal

Compliance2 records

Visiopharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Visiopharm leadership team

Management profile

Number of profiles

Profiles3 records

Visiopharm funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Visiopharm M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Visiopharm

What does Visiopharm do?

Visiopharm develops and sells AI-driven precision pathology software for tissue image analysis in both research and clinical diagnostics. Its platform combines deep learning algorithms with 20 years of pathology expertise, offering core products (Discovery, Phenoplex, Insight for Diagnostics), add-on modules (Qualitopix, Tissuealign, Tissuearray), and a library of over 130 modular analysis APPs. The portfolio includes nine IVDR-cleared CE-IVD diagnostic algorithms for clinical decision support in cancer diagnostics.

Is Visiopharm a public or private company?

Visiopharm is a private company. It is classified as corporate owned and is currently acquired.

When was Visiopharm founded?

Visiopharm was founded in 2002. It employs 51 to 100 people.

Where is Visiopharm based?

Visiopharm is headquartered in Hørsholm, Denmark, in the Europe region.

How does Visiopharm make money?

Four revenue lines are on record. Software Licenses are the primary driver. The others are software Maintenance Service, professional Services and training Services.

Who are Visiopharm's main competitors?

Direct peers on record are Proscia, PathAI and Indica Labs. Broad incumbents are Aperio (Leica Biosystems), Philips Digital Pathology, Hamamatsu Photonics and Roche (uPath/Aperio combo). Emerging players are Akoya Biosciences, Ibex Medical Analytics and QuPath.

Does Visiopharm have an API?

No public API is recorded for Visiopharm.

What industry is Visiopharm in?

Visiopharm's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 3391 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Grundium Acquires AI Precision Pathology Software Provider VisiopharmGrundium, a Finland-based digital pathology scanner company backed by EW Healthcare Partners, has acquired Denmark-based Visiopharm, an AI-driven precision pathology software provider, to create an integrated precision pathology platform combining digital slide scanning with AI-powered diagnostic applications. The combined entity will serve diagnostic laboratories, biopharmaceutical development, and research organizations across more than 40 countries, with both companies continuing to support existing customers while offering integrated solutions over time. The acquisition is positioned as a transformational step in building a comprehensive digital and computational pathology platform targeting the growing precision diagnostics market, particularly in oncology.EU-StartupsFinland’s Grundium acquires Denmark’s Visiopharm to build an end-to-end AI precision pathology platformGrundium, a Tampere-based digital pathology imaging startup, has acquired Visiopharm, a Denmark-based provider of AI-driven precision pathology software, from an undisclosed seller. The combined entity integrates Grundium's compact scanner portfolio with Visiopharm's AI-powered image analysis tools and nine IVDR-cleared diagnostic algorithms to create an end-to-end platform for diagnostic laboratories, biopharmaceutical research, and clinical applications. Both companies will continue supporting their existing products independently while offering customers the option to combine capabilities, and the acquisition builds on a pre-existing integration partnership between the two firms.BebeezFinland’s Grundium acquires Denmark’s Visiopharm to build an end-to-end AI precision pathology platform – BeBeez InternationalGrundium, a Tampere-based digital pathology startup backed by EW Healthcare Partners, has acquired Denmark's Visiopharm, a provider of AI-driven precision pathology software, in a deal that combines complementary imaging and AI capabilities into a single end-to-end platform. The merged entity aims to serve diagnostic laboratories, biopharmaceutical developers, and researchers with a broader range of digital pathology solutions spanning individual lab workflows to enterprise-scale deployments. The acquisition strengthens a prior partnership between the two companies, with both product lines continuing to be supported independently while enabling customers to combine capabilities as needed.VisiopharmGrundium acquires Visiopharm to create integrated precision pathology platformGrundium acquired Visiopharm to combine digital slide scanning with AI-driven precision pathology software. The combined platform targets diagnostic laboratories, biopharmaceutical development, and research, with existing customers able to continue using either product independently.PharmiWeb.comGrundium Acquires Visiopharm to Create Integrated Precision Pathology PlatformGrundium Oy, a Finland-based digital pathology scanner company backed by US healthcare private equity firm EW Healthcare Partners, has acquired Denmark-based Visiopharm A/S, an AI-driven precision pathology software company, to create an integrated end-to-end platform for diagnostic laboratories and biopharmaceutical research. The combined entity brings together Grundium's compact slide scanning technology with Visiopharm's AI-powered biomarker analysis tools, enabling scalable digital pathology workflows from individual laboratory workflows to enterprise-scale deployments. Both companies' products will continue to be supported independently while offering customers the option to combine capabilities as their needs evolve.Irw-PressGrundium Acquires Visiopharm to Create Integrated Precision Pathology PlatformGrundium Oy, a Finnish digital pathology scanner company backed by EW Healthcare Partners, has acquired Visiopharm A/S, a Danish AI-driven precision pathology software company, to create an integrated end-to-end platform for diagnostic laboratories and biopharmaceutical research. The combined entity brings together Grundium's imaging technology with Visiopharm's nine IVDR-cleared diagnostic algorithms and over 750 customer accounts across 40 countries. The acquisition builds on an existing partnership and is described by EW Healthcare Partners as a transformational step toward building a comprehensive digital and computational pathology platform.Stock TitanAgilent to feature PD-L1, digital pathology at USCAPAgilent Technologies announced it will showcase advances in precision oncology and digital pathology at the 2026 USCAP Annual Meeting in San Antonio, Texas, from March 21-26. The company will highlight a new PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, expanding its existing PD-L1 diagnostic portfolio. Agilent will also demonstrate end-to-end digital pathology workflows in collaboration with ecosystem partners including Hamamatsu, Proscia, PathAI, and Visiopharm, hosting educational sessions featuring presentations from pathologists and industry executives.BioSpaceAgilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026Agilent Technologies announced it will showcase its latest advances in precision oncology and digital pathology workflows at the 2026 USCAP Annual Meeting in San Antonio, Texas from March 21-26. The company highlighted an expanded PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, alongside end-to-end digital pathology workflows designed to improve laboratory efficiency and reproducibility. Agilent also emphasized collaborations with ecosystem partners including Hamamatsu, Proscia, PathAI, and Visiopharm to support open adoption of digital pathology technologies.Fraunhofer ISEDigital Pathology AI Companies — List of Commercial AIs (CE-IVDR, FDA, RUO)The article provides an updated overview of the commercial digital pathology AI market as of July 2025, noting that over 100 products from more than 30 vendors have achieved CE-IVDR or FDA clearance. It highlights key industry players such as Paige.AI, Visiopharm, and Proscia, while analyzing current trends in regulatory approval rates and clinical adoption strategies. The piece also outlines ideal automated workflows for integrating these AI tools into laboratory information systems.PaigePathAI Announces Integrations with Leading AI-pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management System — Paige.aiPathAI announced the integration of several AI products from digital pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System in Boston, MA on November 19, 2024. These collaborations aim to enhance diagnostics and improve patient care by providing access to advanced algorithms and streamlining pathology workflows. The integrations signal PathAI's commitment to interoperability and advancing digital pathology solutions.